The Quality Lowdown: Quality Vision Falls Short At Various US and Indian Facilities
Executive Summary
Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.
You may also be interested in...
Cadila Shifts US Injectables Production From Plant After Tough FDA Inspection
Expert investigators found many problems at Ahmedabad plant, warning letter and Form 483 report show.
US FDA Warns Lupin Again About Poor Batch Failure Investigations
Agency demands review of invalidated out-of-specification findings as root causes of failures continue to elude Indian drugmaker at multiple facilities.
Do Not Be So Quick To Blame Microbes On The Lab, The US FDA Warns Emcure
Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.